SOURCE: WayPoint Biomedical, Inc.

April 10, 2006 11:58 ET

WayPoint Biomedical Begins the Auditing Process to Become a Fully Reporting Company on the Bulletin Boards

HUNTINGTON BEACH, CA -- (MARKET WIRE) -- April 10, 2006 -- WayPoint Biomedical, Inc. (OTC: WYPH) is currently in the process of completing their Company audits in order to complete and submit their SB-2 filing in order to progress up to the OTC Bulletin Boards.

WayPoint has contracted Las Vegas, NV based SEC Certified Accounting and Auditing firm, Moore & Associates, Chartered to complete the financial review, while Portland, Oregon based Robert Laskowski will handle the SEC legal oversight of this transition.

WayPoint CEO, Dennis Shepherd, comments, "With the audit already underway, we hope to see WayPoint become a fully reporting company within the next two months. Moving to the OTC:BB should help to instill greater investor confidence and enhance shareholder value, which is an integral component of our corporate goals." Mr. Shepherd further states, "With the market responding favorably to recent events, such as the formation of our new Joint Venture, World Wide Medical Systems, we still believe our stock is still undervalued."

About WayPoint Biomedical:

WayPoint Biomedical, Inc., a wholly owned subsidiary of WayPoint Biomedical Holdings, Inc. (OTC: WYPB), is an innovative biomedical technology firm, specializing in diagnostic tests and devices for screening and monitoring human health, fitness and environment. The Company develops and markets cutting-edge disposable rapid tests that offer both a preliminary diagnostic screen to specific conditions, along with a future path for consumers, medical providers, and first responders to follow regarding their health status or environmental condition. WayPoint's unique and affordable home-based and on-site tests are focused on detecting the cause of a disease or pathogen, as opposed to determining the symptom; becoming a part of the solution to help reverse the escalating cost of Healthcare. For more information on WayPoint Biomedical visit,

Included in this release are certain "forward-looking'' statements, involving risks and uncertainties, which are covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including statements regarding WayPoint's performance. Such statements are based on management's current expectations and are subject to certain factors, risks and uncertainties that may cause actual results, events and performance to differ materially from those referred to or implied by such statements. In addition, actual future results may differ materially from those anticipated, depending on a variety of factors, including continued maintenance of favorable license arrangements, success of market research identifying new product opportunities, successful introduction of new products, continued product innovation, the success of enhancements to WayPoint's brand image, sales and earnings growth, ability to attract and retain key personnel, and general economic conditions affecting consumer spending, including uncertainties relating to global political conditions, such as terrorism. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. WayPoint Biomedical does not intend to update any of the forward-looking statements after the date of this release to conform these statements to actual results or to changes in its expectations, except as may be required by law.

Contact Information